跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
FOXP3
首页
药物
FOXP3
FOXP3
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
CD127 EXPRESSION INVERSELY CORRELATES WITH FOXP3 AND SUPPRESSIVE FUNCTION OF CD4+ TREGS
EP 3431585 A1
申请人: UNIV CALIFORNIA
优先权: 2006
EP
US
WO
12 件公开
METHOD FOR TREATING AUTOIMMUNE DISEASE USING CD4 T-CELLS WITH ENGINEERED STABILIZATION OF EXPRESSION OF ENDOGENNOUS FOXP3 GENE
EP 3532105 B1
申请人: SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST
优先权: 2016
CN
EP
US
WO
8 件公开
ENGINEERED REGULATORY T CELLS
EP 3997212 B1
申请人: THE CHILDRENS MERCY HOSPITAL
优先权: 2019
EP
US
WO
7 件公开
EXPRESSION OF FOXP3 IN EDITED CD34+ CELLS
EP 3784690 A4
申请人: SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST
优先权: 2018
CN
EP
US
WO
6 件公开
REDUCER OF IMMUNOSUPPRESSION BY TUMOR CELL AND ANTITUMOR AGENT USING THE SAME
US 2010291677 A1
申请人: UNIV KEIO
优先权: 2007
CN
EP
US
5 件公开
EXPRESSION OF HUMAN FOXP3 IN GENE EDITED T CELLS
EP 3784689 A4
申请人: SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST
优先权: 2018
CN
EP
US
WO
4 件公开
ARTIFICIAL ANTIGEN-SPECIFIC IMMUNOREGULATORY T (AIRT) CELLS
EP 3989987 A4
申请人: SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST
优先权: 2019
CN
EP
US
WO
4 件公开
COMPOSITIONS AND METHODS FOR MODULATING FORKHEAD BOX P3 (FOXP3) GENE EXPRESSION
EP 4118207 A1
申请人: OMEGA THERAPEUTICS INC
优先权: 2020
CN
EP
US
WO
4 件公开
TUMOUR BIOMARKERS FOR IMMUNOTHERAPY
EP 4150347 A1
申请人: KYMAB LTD
优先权: 2020
CN
EP
US
WO
4 件公开
CRISPR-BASED FOXP3 GENE ENGINEERED T CELLS AND HEMATOPOIETIC STEM CELL PRECURSORS TO TREAT IPEX SYNDROME PATIENTS
EP 4103591 A2
申请人: UNIV LELAND STANFORD JUNIOR
优先权: 2020
EP
US
WO
4 件公开
第 1 / 10 页
上一页
下一页
药物
反馈